Welcome to
a movement
in muscle
Muscle moves us.
From inertia to innovation. From possibility to promise. From unmet need to novel therapies.
At Edgewise, we’re bringing our unique expertise and singular focus on muscle science to develop novel therapeutics for serious skeletal and cardiac muscle diseases – with determination, integrity and a strong commitment to patients.
But our movement in muscle doesn’t end there.
Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.
Our Focus:
Serious Muscle Diseases With Life-limiting Impact
Cardiovascular Diseases
Advancing EDG-7500, a novel oral, selective cardiac sarcomere modulator for hypertrophic cardiomyopathy.
Muscular Dystrophy
Exploring sevasemten, an orally administered first-in-class fast skeletal myosin inhibitor for Becker, Duchenne, and other muscular dystrophies.
Inspired by
patients and families
We honor the experience of individuals and families living with and facing the challenges of serious muscle disease. Our commitment to bringing life-changing medicines is inspired by their strength and courage.
Muscular thinking.
Courageous commitment.
Our science-driven culture places patients first as we start with their unmet need then work towards developing therapies to help address the significant challenges of serious muscle diseases.
Add muscle to your career
We built a company that’s inspirational, pioneering, science-forward and always reaching new heights. Learn more about what it’s like to work with us—globally or at our headquarters—and elevate your career to the next level.
Latest News
Nov. 7, 2024
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Oct. 1, 2024
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
Sep. 19, 2024
